Frequently Asked Questions

AFINITOR® (everolimus) Tablets

Find Answers to Common Questions About AFINITOR

Expand all

AFINITOR® (everolimus) Tablets is a once-daily oral prescription medicine used with the medicine exemestane to treat advanced HR+, HER2- breast cancer in postmenopausal women who have already received certain other medicines for their disease.

AFINITOR® (everolimus) Tablets plus the medicine exemestane is for postmenopausal women with advanced HR+, HER2- breast cancer who have already received certain other medicines for their disease.

Learn about HR+, HER2- breast cancer here >

The combination of AFINITOR® (everolimus) Tablets plus exemestane works on 2 key pathways to help slow the growth and spread of cancer cells. AFINITOR can also affect noncancerous cells. Although AFINITOR has been studied in patients with HR+, HER2- breast cancer, how AFINITOR works has only been demonstrated in laboratory studies.

Combination therapy is a treatment strategy of taking multiple medicines to fight your disease. With combination therapy, you’ll have 2 medicines working together to help you fight your metastatic HR+, HER2- breast cancer in 2 ways instead of 1.

In a clinical trial, AFINITOR® (everolimus) Tablets was shown to double the time patients lived without the disease getting worse compared with exemestane alone. Data have not shown an increase in overall survival.

AFINITOR® (everolimus) Tablets can cause serious side effects, such as lung or breathing problems, infections, or kidney failure. Some of these side effects can be severe and can even lead to death. Mouth sores (also called stomatitis) are common during treatment with AFINITOR and can be severe. Your health care team may have ways to help manage side effects that do occur. It’s important to talk with your doctor or nurse about side effects you experience and the best ways to manage them.

Learn more here >

To help manage a common side effect called stomatitis, or mouth sores, your doctor may prescribe an alcohol-free dexamethasone oral solution. This prescription-only medication may reduce the likelihood of mouth sores occurring, or reduce the severity if they do occur. Always follow your doctor's instructions, and contact your doctor or nurse if you are having any problems.

Take AFINITOR® (everolimus) Tablets exactly as prescribed by your health care provider. Swallow AFINITOR tablets whole with a glass of water. Do not take any tablet that is broken or crushed. You should take AFINITOR one time each day at about the same time. Take AFINITOR the same way each time, either with food or without food.

Learn more about taking AFINITOR >

If you take too much AFINITOR® (everolimus) Tablets, contact your health care provider or go to the nearest hospital emergency room right away. Take the pack of AFINITOR with you. If a dose is missed, you may take it if it is less than 6 hours; if more than 6 hours have passed, skip that dose and take AFINITOR as usual the next day. Do not take 2 doses to replace a missed dose. If you’re not sure what to do, call your health care provider.

Don’t drink grapefruit juice or eat grapefruit during your treatment with AFINITOR® (everolimus) Tablets. It may make the amount of AFINITOR in your blood increase to a harmful level. Tell your health care provider about all medications and herbal supplements (eg, St John's Wort) you are taking, or if you start or stop any medications/supplements while taking AFINITOR.

Novartis Pharmaceuticals Corporation is committed to helping make treatment with AFINITOR® (everolimus) Tablets as affordable as possible.

Learn about Financial Resources >

For additional support information or to speak to our one our AFINITOR® (everolimus) Tablets representatives call 1-888-4-AFINITOR.

It's important to remember that while these calls are designed to be useful, they do not take the place of regular, open communication with your health care team. Always follow your doctor's instructions during treatment with AFINITOR, and contact your doctor or nurse if you are having any problems or concerns.